Biology subjects

Taroni, J. N.

Publications and source records attributed to Taroni, J. N..

9 recordsLinked to original sources

bioRxiv2026

Uniformly processed transcriptome-wide alternative splicing profiles for pediatric cancer research

Alterations in regulatory processes like alternative splicing contribute to pediatric cancer development. Although splicing aberrations have been observed in pediatric leukemias, alternative splicing has yet to be studied in pediatric cancers at scale, due to a lack of uniformly processed, sample-level pediatric cancer splicing profiles with non-diseased tissue comparators. We address this need by quantifying splice event usage for a curated set of bulk RNA-seq datasets from the NCI's Therapeutically Applicable Research to Generate Effective Treatments (TARGET, n = 1152) and Genotype-Tissue Expression (GTEx, n = 1098) as a comparator. This Treehouse Splice Compendium is accompanied by a reproducible workflow that was used to generate the data in the compendium and reflects the largest known RNA-seq dataset processed by the splice quantification tool Shiba. The compendium is part of a suite of large, uniformly processed datasets aggregated by the UCSC Treehouse Childhood Cancer Initiative and Alex's Lemonade Stand Foundation's Childhood Cancer Data Lab, which include the Treehouse Expression Compendia, refine.bio, and the Single-cell Pediatric Cancer Atlas.

bioinformatics↗

bioRxiv2024

The Single-cell Pediatric Cancer Atlas: Data portal and open-source tools for single-cell transcriptomics of pediatric tumors

The Single-cell Pediatric Cancer Atlas (ScPCA) Portal (https://scpca.alexslemonade.org/) is a data resource for uniformly processed single-cell and single-nuclei RNA sequencing (RNA-seq) data and de-identified metadata from pediatric tumor samples. Originally comprised of data from 10 projects funded by Alexs Lemonade Stand Foundation (ALSF), the Portal currently contains summarized gene expression data for over 700 samples across 55 cancer types from ALSF-funded and community-contributed datasets. Downloads include gene expression data as SinglecellExperiment or AnnData objects containing raw and normalized counts, PCA and UMAP coordinates, and automated cell type annotations, along with summary reports. Some samples have additional data from bulk RNA-seq, spatial transcriptomics, and/or feature barcoding (e.g., CITE-seq and cell hashing) included in the download. All data on the Portal were uniformly processed using scpca-nf, an efficient and open-source Nextflow workflow that uses alevin-fry to quantify gene expression. Comprehensive documentation, including descriptions of file contents and a guide to getting started, is available at https://scpca.readthedocs.io.

bioinformatics↗

bioRxiv2021

GenomicSuperSignature: interpretation of RNA-seq experiments through robust, efficient comparison to public databases

Millions of transcriptomic profiles have been deposited in public archives, yet remain underused for the interpretation of new experiments. We present a novel method for interpreting new transcriptomic datasets through near-instantaneous comparison to public archives without high-performance computing requirements. We performed Principal Component Analysis on 536 studies comprising 44,890 RNA sequencing profiles. Sufficiently similar loading vectors were aggregated to form Replicable Axes of Variation (RAV). RAVs were annotated with metadata of originating studies and samples and by gene set enrichment analysis. Functionality to associate new datasets with RAVs, extract interpretable annotations, and provide intuitive visualization are implemented as the GenomicSuperSignature R/Bioconductor package. We demonstrated the efficient and coherent database searching, robustness to batch effects and heterogeneous training data, and transfer learning capacity of our method using TCGA and rare diseases datasets. GenomicSuperSignature will aid analyzing new gene expression data in the context of existing databases using minimal computing resources. PURPOSEMillions of transcriptomic profiles have been deposited in public archives, yet remain underused for the interpretation of new experiments. Existing methods for leveraging these public resources have focused on the reanalysis of existing data or analysis of new datasets independently. We present a novel approach to interpreting new transcriptomic datasets by near-instantaneous comparison to public archives without high-performance computing requirements. METHODSTo identify replicable and interpretable axes of variation in any given gene expression dataset, we performed Principal Component Analysis (PCA) on 536 studies comprising 44,890 RNA sequencing profiles. Sufficiently similar loading vectors, when compared across studies, were aggregated to form Replicable Axes of Variation (RAV). RAVs were annotated with metadata of originating studies and samples and by gene set enrichment analysis. Functionality to associate new datasets with RAVs, extract interpretable annotations, and provide intuitive visualization are implemented as the GenomicSuperSignature R/Bioconductor package. RESULTSRAVs are robust to batch effects and the presence of low-quality or irrelevant studies, and identify signals that can be lost by merging samples across the training datasets. The GenomicSuperSignature package allows instantaneous matching of PCA axes in new datasets to pre-computed RAVs, cutting down the analysis time from days to the order of seconds on an ordinary laptop. We demonstrate that RAVs associated with a phenotype can provide insight into weak or indirectly measured biological attributes in a new study by leveraging accumulated data from published datasets. Benchmarking against complementary previous works demonstrates that the RAV index 1) identifies colorectal carcinoma transcriptome subtypes that are similar to but more correlated with clinicopathological characteristics than previous disease-specific efforts and 2) can estimate neutrophil counts through transfer learning on new data comparably to the previous efforts despite major differences in training datasets and model building processes with the additional benefits of flexibility and scalability of the model application. CONCLUSIONGenomicSuperSignature establishes an information resource and software tools to interrogate it. Prior knowledge databases are coherently linked, enabling researchers to analyze new gene expression data in the context of existing databases using minimal computing resources. The robustness of GenomicSuperSignature suggests that we can expand this approach beyond human gene expression profiles, such as single-cell RNA-seq, microbiome abundance, and different species transcriptomics datasets.

bioinformatics↗

bioRxiv2020

Integrative analysis identifies candidate tumor microenvironment and intracellular signaling pathways that define tumor heterogeneity in NF1

Neurofibromatosis type 1 is a monogenic syndrome that gives rise to numerous symptoms including cognitive impairment, skeletal abnormalities, and growth of benign nerve sheath tumors. Nearly all NF1 patients develop cutaneous neurofibromas (cNFs), which occur on the skin surface, while 40-60% of patients develop plexiform neurofibromas (pNFs) which are deeply embedded in the peripheral nerves. Patients with pNFs have a [~]10% lifetime chance of these tumors becoming malignant peripheral nerve sheath tumors (MPNSTs). These tumors have a severe prognosis and few treatment options other than surgery. Given the lack of therapeutic options available to patients with these tumors, identification of druggable pathways or other key molecular features could aid ongoing therapeutic discovery studies. In this work, we used statistical and machine learning methods to analyze 77 NF1 tumors with genomic data to characterize key signaling pathways that distinguish these tumors and identify candidates for drug development. We identified subsets of latent gene expression variables that may be important in the identification and etiology of cNFs, pNFs, other neurofibromas, and MPNSTs. Furthermore, we characterized the association between these latent variables and genetic variants, immune deconvolution predictions, and protein activity predictions.

systems biology↗

bioRxiv2019

annoFuse: an R Package to annotate and prioritize putative oncogenic RNA fusions

BackgroundGene fusion events are a significant source of somatic variation across adult and pediatric cancers and are some of the most clinically-effective therapeutic targets, yet low consensus of RNA-Seq fusion prediction algorithms makes therapeutic prioritization difficult. In addition, events such as polymerase read-throughs, mis-mapping due to gene homology, and fusions occurring in healthy normal tissue require informed filtering, making it difficult for researchers and clinicians to rapidly discern gene fusions that might be true underlying oncogenic drivers of a tumor and in some cases, appropriate targets for therapy. ResultsWe developed annoFuse, an R package, and shinyFuse, a companion web application, to annotate, prioritize, and explore biologically-relevant expressed gene fusions, downstream of fusion calling. We validated annoFuse using a random cohort of TCGA RNA-Seq samples (N = 160) and achieved a 96% sensitivity for retention of high-confidence fusions (N = 603). annoFuse uses FusionAnnotator annotations to filter non-oncogenic and/or artifactual fusions. Then, fusions are prioritized if previously reported in TCGA and/or fusions containing gene partners that are known oncogenes, tumor suppressor genes, COSMIC genes, and/or transcription factors. We applied annoFuse to fusion calls from pediatric brain tumor RNA-Seq samples (N = 1,028) provided as part of the Open Pediatric Brain Tumor Atlas (OpenPBTA) Project to determine recurrent fusions and recurrently-fused genes within different brain tumor histologies. annoFuse annotates protein domains using the PFAM database, assesses reciprocality, and annotates gene partners for kinase domain retention. As a standard function, reportFuse enables generation of a reproducible R Markdown report to summarize filtered fusions, visualize breakpoints and protein domains by transcript, and plot recurrent fusions within cohorts. Finally, we created shinyFuse for algorithm-agnostic interactive exploration and plotting of gene fusions. ConclusionsannoFuse provides standardized filtering and annotation for gene fusion calls from STARFusion and Arriba by merging, filtering, and prioritizing putative oncogenic fusions across large cancer datasets, as demonstrated here with data from the OpenPBTA project. We are expanding the package to be widely-applicable to other fusion algorithms and expect annoFuse to provide researchers a method for rapidly evaluating, prioritizing, and translating fusion findings in patient tumors.

bioinformatics↗

bioRxiv2018

Inflammatory and JAK-STAT Pathways as Shared Molecular Targets for ANCA-Associated Vasculitis and Nephrotic Syndrome

BackgroundGlomerular diseases of the kidney are presently differentiated, diagnosed and treated according to conventional clinical or structural features. While etiologically diverse, these diseases share common clinical features including but not limited to reduced glomerular filtration rate, increased serum creatinine and proteinuria suggesting shared pathogenic mechanisms across diseases. Renal biopsies from patients with nephrotic syndrome (NS) or ANCA-associated vasculitis (AAV) were evaluated for molecular signals cutting across conventional disease categories as candidates for therapeutic targets.\n\nMethodsRenal biopsies were obtained from patients with NS (minimal change disease, focal segmental glomerulosclerosis, or membranous nephropathy) (n=187) or AAV (granulomatosis with polyangiitis or microscopic polyangiitis) (n=80) from the Nephrotic Syndrome Study Network (NEPTUNE) and the European Renal cDNA Bank. Transcriptional profiles were assessed for shared disease mechanisms.\n\nResultsIn the discovery cohort, 10-25% transcripts were differentially regulated versus healthy controls in both NS and AAV, >500 transcripts were shared across diseases. The majority of shared transcripts (60-77%) were validated in independent samples. Therapeutically targetable networks were identified, including inflammatory JAK-STAT signaling. STAT1 eQTLs were identified and STAT1 expression associated with GFR-based outcome. A transcriptional STAT1 activity score was generated from STAT1-regulated target genes which correlated with CXCL10 (p<0.001), a JAK-STAT biomarker, predictors of CKD progression, interstitial fibrosis (r=0.41, p<0.001), and urinary EGF (r=-0.51, p<0.001).\n\nConclusionAAV and NS caused from histopathologically distinct disease categories share common intra-renal molecular pathways cutting across conventional disease classifications. This approach provides a starting point for de novo drug development, and repurposing efforts in rare kidney diseases.

systems biology↗

bioRxiv2018

MultiPLIER: a transfer learning framework reveals systemic features of rare autoimmune disease

Unsupervised machine learning methods provide a promising means to analyze and interpret large datasets. However, most gene expression datasets generated by individual researchers remain too small to fully benefit from these methods. In the case of rare diseases, there may be too few cases available, even when multiple studies are combined. We trained a Pathway Level Information ExtractoR (PLIER) model using on a large public data compendium comprised of multiple experiments, tissues, and biological conditions. We then transferred the model to small rare disease datasets in an approach we term MultiPLIER. Models constructed from large, diverse public data i) included features that aligned well to important biological factors; ii) were more comprehensive than those constructed from individual datasets or conditions; iii) transferred to rare disease datasets where the models describe biological processes related to disease severity more effectively than models trained on specifically those datasets.

bioinformatics↗

bioRxiv2017

Cross-Platform Normalization Enables Machine Learning Model Training On Microarray And RNA-Seq Data Simultaneously

MotivationLarge compendia of gene expression data have proven valuable for the discovery of novel biological relationships. The majority of available RNA assays are run on microarray, while RNA-seq is becoming the platform of choice for new experiments. The data structure and distributions between the platforms differ, making it challenging to combine them. We performed supervised and unsupervised machine learning evaluations, as well as differential expression analyses, to assess which normalization methods are best suited for combining microarray and RNA-seq data.\n\nResultsWe find that quantile and Training Distribution Matching normalization allow for supervised and unsupervised model training on microarray and RNA-seq data simultaneously. Nonparanormal normalization and z-scores are also appropriate for some applications, including differential expression analysis.\n\nAvailability and ImplementationThese analyses were performed in R and are available at https://www.github.com/greenelab/RNAseq_titration_results under a BSD-3 clause license.\n\nContactcsgreene@upenn.edu\n\nSupplementary Information is available.

bioinformatics↗

bioRxiv2016

A functional genomic meta-analysis of clinical trials in systemic sclerosis: towards precision medicine and combination therapy

Systemic sclerosis (SSc) is an orphan, systemic autoimmune disease with no FDA-approved treatments. Its heterogeneity and rarity often result in underpowered clinical trials making the analysis and interpretation of associated molecular data challenging. We performed a meta-analysis of gene expression data from skin biopsies of SSc patients treated with five therapies: mycophenolate mofetil (MMF), rituximab, abatacept, nilotinib, and fresolimumab. A common clinical improvement criterion of -20% OR -5 modified Rodnan Skin Score was applied to each study. We developed a machine learning approach that captured features beyond differential expression that was better at identifying targets of therapies than the differential expression alone. Regardless of treatment mechanism, abrogation of inflammatory pathways accompanied clinical improvement in multiple studies suggesting that high expression of immune-related genes indicates active and targetable disease. Our framework allowed us to compare different trials and ask if patients who failed one therapy would likely improve on a different therapy, based on changes in gene expression. Genes with high expression at baseline in fresolimumab non-improvers were downregulated in MMF improvers, suggesting that immunomodulatory or combination therapy may have benefitted these patients. This approach can be broadly applied to increase tissue-specificity and sensitivity of differential expression results.

genomics↗